4925 Results

People

  1. Giralt
    Giralt
  2. Berger
    Berger
  3. Morrow
    Morrow
  4. Horwitz
    Horwitz
  5. Ladanyi
    Ladanyi
  6. Lee
    Lee
  7. Adusumilli
    Adusumilli
  8. Hyman
    Hyman
  9. Perales
    Perales
  10. Solit
    Solit

Groups

  1. Department of Medicine (2037)
  2. GSK Faculty (1130)
  3. Solid Tumor Oncology Division (1105)
  4. Sloan Kettering Institute Postdocs (1022)
  5. Surgery (893)
  6. Survivorship Research (780)
  7. Center for Hematologic Malignancies (764)
  8. Hematologic Malignancies, Division of (714)
  9. Department of Pathology and Laboratory Medicine (653)
  10. Population Sciences Research Program (632)
  1. "2017"
Formats
  1. Journal Article (3053)
  2. Meeting Abstract (1581)
  3. Book Section (242)
  4. Conference Paper (35)
  5. Book Whole (12)
  6. Editorial (1)
  7. Review (1)
Groups
  1. Department of Medicine (2037)
  2. GSK Faculty (1130)
  3. Solid Tumor Oncology Division (1105)
  4. Sloan Kettering Institute Postdocs (1022)
  5. Surgery (893)
  6. Survivorship Research (780)

More Groups

People
  1. Sergio Giralt (86)
  2. Jose Baselga (68)
  3. Michael Berger (67)
  4. Monica Morrow (65)
  5. Jedd Wolchok (62)
  6. Martin Tallman (61)

More People

Years
  1. 2017 (4925)
Publications
  1. Journal of Clinical Oncology (349)
  2. Blood (233)
  3. Annals of Oncology (123)
  4. International Journal of Radiation Oncology, Biology, Physics (122)
  5. Modern Pathology (85)
  6. Laboratory Investigation (76)

More Publications

Publishers
  1. Elsevier Inc. (599)
  2. Springer (383)
  3. American Society of Clinical Oncology (378)
  4. Nature Publishing Group (310)
  5. Oxford University Press (280)
  6. American Society of Hematology (246)

More Publishers

Results (4925)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes
    Meeting Abstract

    Scher, H.; Graf, R. P.; Jendrisak, A.; McLaughlin, B.; Barnett, E.; Schreiber, N. A.; Lee, J.; Kelvin, J.; Wang, Y.; Landers, M.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • LKB1 loss is a novel genomic predictor of de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma
    Meeting Abstract

    Skoulidis, F.; Hellman, M. D.; Awad, M.; Gainor, J. F.; Rizvi, H.; Carter, B.; Denning, W. L.; Villalobos, P.; Parra, E. R.; Elamin, Y. Y.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma
    Meeting Abstract

    Payton, M.; Pinchasik, D.; Mehta, A.; Goel, S.; Zain, J. M.; Sokol, L.; Jacobsen, E.; Patel, M. R.; Horwitz, S. M.; Meric-Bernstam, F.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • AGATA molecular screening program: Implementing precision medicine in patients with advanced breast cancer in Spain
    Meeting Abstract

    Simon, S. P.; Gonzalez, P. V.; Vivancos, A.; Prat, A.; Scaltriti, M.; Burgues, O.; Rodon, J.; Canes, J.; Lluch, A.; Llombart, A.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator's choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc)
    Meeting Abstract

    Petrylak, D.; Vogelzang, N. J.; Fradet, Y.; Bajorin, D.; de Wit, R.; Vaughn, D. J.; Lee, J. L.; Fong, L.; Climent, M. A.; Necchi, A.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Powles, T.; McDermott, D. F.; Rini, B.; Motzer, R. J.; Atkins, M. B.; Fong, L.; Joseph, R. W.; Pal, S. K.; Ravaud, A.; Bracarda, S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)
    Meeting Abstract

    Powles, T.; Motzer, R. J.; George, D. J.; Jonasch, E.; Pal, S.; Tannir, N. M.; Signoretti, S.; Mai, T. H.; Scheffold, C.; Wang, E.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Sequential chemo-chemoradiation (CCRT) in locally advanced pancreas cancer in an Irish high volume centre
    Meeting Abstract

    Abdul Rahman, R.; Teo, M. Y.; Moriarty, M.; McDermott, R.; McVey, G.
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Genomic analyses reveal potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy
    Meeting Abstract

    Radosevic-Robin, N.; Cocco, E.; Won, H. H.; Berger, M. F.; Privat, M.; Abrial, C.; Penault-Llorca, F.; Scaltriti, M.
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1/2 study of the selective TRK inhibitor larotrectinib, in pediatric patients with cancer
    Meeting Abstract

    Gallego MeĢlcon, S.; Casanova, M.; Bielack, S.; Chisholm, J.; van Tilburg, C. S.; Federman, N.; Albert, C. M.; Mascarenhas, L.; Turpin, B.; Nagasubramanian, R.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save